Helicobacter pylori related and non-related lesions in the stomach

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 4, 2011, Pages 395-404

  Venerito, M ^a   Wex, T ^a   Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Anti inflammatory agents, non steroidal; Helicobacter pylori; Stomach ulcer

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CELECOXIB; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ATROPHY; BEDTIME DOSAGE; CARDIOVASCULAR RISK; DIFFERENTIAL DIAGNOSIS; GASTRIC ULCER BLEEDING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; STOMACH ATROPHY; STOMACH CANCER; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER HEMORRHAGE; STOMACH ULCER;

EID: 84856511857     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Spechler SJ. Peptic ulcer disease and its complications. In: Feldman M, Friedman LS, Sleisenger MH, editors. Sleisenger and Fordtran's gastrointestinal and liver disease. 7th ed. Philadelphia, PA: W.B. Saunders Company; 2002.
2. Yeomans ND, Naesdal J. Systematic review: ulcer definition in NSAID ulcer prevention trials. Aliment Pharmacol Ther 2008;27:465-72. (Pubitemid 351300861)
3. Cryer B, Spechler SJ. Peptic ulcer disease. Sleisenger and Fortran's Gastrointestinal and Liver Disease. 8th ed.
4. Pounder R. Silent peptic ulceration: deadly silence or golden silence? Gastroenterology 1989;96:626-31. (Pubitemid 19038538)
5. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet 2009;374:1449-61.
6. Tummala S, Keates S, Kelly CP. Update on the immunologic basis of Helicobacter pylori gastritis. Curr. Opin. Gastroenterol 2004;20:592-7. (Pubitemid 39447170)
7. Amieva MR and El Omar EM. Host-Bacterial Interactions in Helicobacter pylori Infection. Gastroenterology 2008;134:306-23. (Pubitemid 350309334)
8. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterol 1997;113:15-24. (Pubitemid 27281753)
9. Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006;55:1545-52. (Pubitemid 44629199)
10. Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010;15(Suppl 1):14-20.
11. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-39.
12. Fischer W, Prassl S, Haas R. Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori. Curr Top Microbiol Immunol 2009;337:129-71.
13. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011;173:259-70.
14. D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter 2009;14(Suppl 1):21-8.
15. Robinson K, Kenefeck R, Pidgeon EL, Shakib S, Patel S, Poison RJ et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008;57:1375-85.
16. Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011;16:1-8.
17. Kandulski A, Malfertheiner P, Wex T. Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer. Anticancer Res 2010;30:1093-103.
18. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006;131:525-37. (Pubitemid 44142446)
19. Schmees C, Prinz C, Treptau T, Rad R, Hengst L, Voland P et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007;132:1820-33. (Pubitemid 46677933)
20. Geben B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003;301:1099-102. (Pubitemid 37022312)
21. Backen S, Naumann M. What a disorder: proinflammatory signaling pathways induced by Helicobacter pylori. Trends Microbiol 2010;18:479-86.
22. Tegtmeyer N, Wessler S, Backen S. Role of the cagpathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 2011;278:1190-202.
23. Gong M, Ling SS, Lui SY, Yeoh KG, Ho B. Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology.2010;139:564-73.
24. Hussain MA, Naveed SA, Sechi LA, Ranjan S, Alvi A, Ahmed I et al. Isocitrate dehydrogenase of Helicobacter pylori potentially induces humoral immune response in subjects with peptic ulcer disease and gastritis. PLoS One 2008;3e1481.
25. Hosseini ME, Oghalaie A, Habibi G, Nahvijoo A, Hosseini ZM, Tashakoripoor M et al. Molecular detection of host cytokine expression in Helicobacter pylori infected patients via semi-quantitative RT-PCR. Indian J Med Microbiol 2010;28:40-4.
26. Goll R, Cui G, Olsen T, Isaksen V, Gruber F, Husebekk A et al. Alterations in antral cytokine gene expression in peptic ulcer patients during ulcer healing and after Helicobacter pylori eradication. Scand J Immunol 2008;67:57-62. (Pubitemid 350209586)
27. Itoh T, Seno H, Kita T, Chiba T, Wakatsuki Y. Th response to Helicobacter pylori differs between patients with gastric ulcer and duodenal ulcer. Scand J Gastroenterol 2005;40:641-7. (Pubitemid 40827525)
28. Jothimani DK, Zanetto U, Owen RJ, Lawson AJ, Wilson PG. An unusual case of gastric erosions. Gut 2009;58:1669.
29. Sykora J, Hejda V, Varvarovská J, Stozicky F, Gottrand F, Siala K. Helicobacter heilmannii related gastric ulcer in childhood. J Pediatr Gastroenterol Nutr 2003;36:410-3. (Pubitemid 39274619)
30. De Bock M, Van den Bulck K, Hellemans A, Daminet S, Coche JC, Debongnie JC et al. Peptic ulcer disease associated with Helicobacter felis in a dog owner. Eur J Gastroenterol Hepatol 2007;19:79-82. (Pubitemid 46066871)
31. Himoto T, Goda F, Okuyama H, Kono T, Yamagami A, Inukai M et al. Cytomegalovirus-associated acute gastric mucosal lesion in an immunocompetent host. Intern Med 2009;48:1521-4.
32. Saxena A, Nath Prasad K, Chand Ghoshal U, Krishnani N, Roshan Bhagat M et al. Association of Helicobacter pylori and Epstein-Barr virus with gastric cancer and peptic ulcer disease. Scand J Gastroenterol 2008;43:669-74. (Pubitemid 351868704)
33. Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, Xinopoulos D, Christodoulou M, Papadokostopoulou A et al. Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol 2005;11:6644-9. (Pubitemid 43072704)
34. Dore MP, Mura D, Deledda S, Maragkoudakis E, Pironti A, Realdi G. Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis: the role of Helicobacter pylori infection and portal hypertensive gastropathy. Can J Gastroenterol 2004;18:521-4. (Pubitemid 39248253)
35. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States, the Slone survey. JAMA 2002;287:337-44. (Pubitemid 34251967)
36. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing, controversial issues and perspectives. Gut 2001;49:443-53. (Pubitemid 32802583)
37. Warner TD, Mitchell JA. Cyclooxygenases, new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804. (Pubitemid 38544498)
38. Weissmann G. Aspirin. Sci Am1991;264:84-90.
39. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase, cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12. (Pubitemid 21892908)
40. Hunt, RH, Bazzoli F. Review article should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004;19:9-16. (Pubitemid 38253486)
41. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation an overview of epidemiologic studies published in the 1990s. Arch Int Med 2000;160:2093-9. (Pubitemid 30482713)
42. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
43. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al. A randomized trial comparing the effect of rofecoxib a COX-2 specific inhibitor to Ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology 1999;117:776-83. (Pubitemid 29468218)
44. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
45. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease a meta-analysis. Lancet 2002;359:14-22. (Pubitemid 34119190)
46. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8. (Pubitemid 40874157)
47. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-21. (Pubitemid 28438573)
48. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. New Engl J Med 2001;344:967-73. (Pubitemid 32240315)
49. Tulassay Z, Stolte M, Sjölund M, Engstrand L, Butruk E, Malfertheiner P et al. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008;20:526-36. (Pubitemid 351667893)
50. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol Hepatol 2011;8:79-88.
51. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
52. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252-5.
53. Goldstein JL, Johanson JF, Hawkey CJ, Suchower LJ, Brown KA. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAlD therapy a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007;26:1101-11. (Pubitemid 47480959)
54. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M et al. International Consensus Upper Gastrointestinal Bleeding Conference Group International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13.
55. Chan FK, Sung JJ, Suen R, Lee YT, Wu JC, Leung WK et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998;12:1201-5. (Pubitemid 28565959)
56. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C. Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs systematic review. BMJ 2004;329:948-57.
57. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. TARGET Study Group Comparison of lumiracoxib with naproxen and Ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74. (Pubitemid 39140622)
58. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2- selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10. (Pubitemid 36174250)
59. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10. (Pubitemid 36015122)
60. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;118:1271-8. (Pubitemid 41566529)
61. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk a double-blind randomised trial. Lancet 2007;369:1621-6. (Pubitemid 46710125)
62. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. A Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102. (Pubitemid 40365350)
63. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
64. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs population based nested case-control analysis. BMJ 2005;330:1366-72.
65. Ray WA, Stein CM, Halt K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease an observational cohort study. Lancet 2002;359:118-23. (Pubitemid 34112540)
66. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhanm GC et al. Nonsteroidal anti-inflammatory drugs acetaminophen and the risk of cardiovascular events. Circulation 2006;113:1578-87. (Pubitemid 43739417)
67. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase- 2 inhibitors and nonselective non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
68. Chan FK, Abraham NS, Scheiman JM, Laine L. First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103:2908-18.
69. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
70. Bandyopadhyay U, Biswas K, Bandyopadhyay D, Ganguly CK, Banerjee RK. Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase-two important gastroprotective enzymes. Mol Cell Biochem 1999;202:31-6. (Pubitemid 30099735)
71. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402. (Pubitemid 39091887)
72. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A et al. Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8. (Pubitemid 44893570)